Skip to content
Screener

NovoCure NVCR Net Income

Net Income at other companies

Boston Scientific logo
Boston ScientificBSX
$907M+14.1%
Medtronic logo
MedtronicMDT
$1.24B+17.8%
Nuvation Bio logo
Nuvation BioNUVB
-$62.84M-6.5%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-$47.32M+57.6%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$45.51M-14.1%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$11.66M-471%

Other financials

Income statement

See full
Revenue$183.6M+15.6%
Gross profit$142.5M+21.4%
Operating income-$10.6M+73.3%
EPS (diluted)-$0.13+63.9%

Balance sheet

See full
Cash & equivalents$93.7M-37.4%
Total debt$37.5M-12.4%
Total equity$338.1M-3.2%
Total assets$795.2M-36.2%

Cash flow

See full
Operating cash flow$8.1M+151%
CapEx$6.9M+26.1%
Free cash flow$1.2M+106%

Valuation

See full
Market cap$1.91B+56.6%
Enterprise value$1.85B+66.6%
P/S2.7×+0.8×

Profitability

See full
Gross margin76.1%-0.3pp
Operating margin-22.1%-3.6pp
Net margin-21.2%-3.8pp
FCF margin-3.6%-1.5pp

Returns & leverage

See full
Return on equity-43.2%-4.0pp
Debt / equity0.1×0.0×
Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:NetIncomeLoss.

The source filing: NovoCure’s 10-Q, filed July 23, 2026.

Filed
Jul 23, 2026, 6:59 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001645113-26-000062
Line itemThree months ended June 30, 2026Three months ended June 30, 2025Six months ended June 30, 2026Six months ended June 30, 2025Year ended December 31, 2025
Total operating costs and expenses153,040156,854355,586311,192642,274
Operating income (loss)(10,562)(39,521)(77,982)(77,386)(153,800)
Financial income (expenses), net(1,890)4,542(3,728)12,11217,550
Income (loss) before income tax(12,452)(34,979)(81,710)(65,274)(136,250)
Income tax3,2065,1605,0869,184(23)
Net income (loss)$(15,658)$(40,139)$(86,796)$(74,458)$(136,227)
Basic and diluted net income (loss) per ordinary share$(0.13)$(0.36)$(0.75)$(0.67)$(1.22)
Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share116,012,397111,572,191115,106,850110,930,576111,471,991

Item 1. Financial Statements

FAQ

What is NovoCure's net income?
NovoCure (NVCR) reported net income of -$15.66M in Q2 2026.
How has NovoCure's net income changed year-over-year?
NovoCure's net income increased by 61.0% year-over-year, from -$40.14M to -$15.66M.
What is the long-term trend for NovoCure's net income?
Over 4 years (2021 to 2025), NovoCure's net income has grown at a 23.6% compound annual growth rate (CAGR), from -$58.35M to -$136.23M.
What does net income mean?
The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.

Ask your AI about NovoCure's net income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude